Inspirex™ Lung

Bioengineered human lung graft for life-saving transplantation


PRESSING NEED

More lung grafts for transplant

The wait for a lung transplant is a race against time. Many patients spend years on the transplant waiting list while facing rejection, complications, or progressive disease before a donor organ becomes available.

Inspirex™ lung advances a potential human lung transplant alternative for patients with limited transplant options and ongoing organ shortages.

MEDICAL BREAKTHROUGH

Inspirex™ Lung

Inspirex™ Lung is an investigational human whole-lung graft designed to increase the number of lungs available for transplantation.


Produced using Xylyx Bio’s proprietary XC™ Platform, Inspirex Lung™ is created by providing systemic physiologic support via xenogeneic cross-circulation to injured donor lungs that would otherwise go unused, with the goal of restoring them to meet standard transplant criteria.

IMPACT

Transforming the future of lung transplantation

Lung transplant volumes have increased only incrementally over the past two decades despite growing patient demand.

The availability of Inspirex™ Lung may help expand access to transplantation, increase the number of viable donor lungs, and reduce lung transplant waitlist mortality in the United States.


  • Organ Procurement & Transplant Network/Scientific Registry of Transplant Recipients. Annual Data Report, 2024.

REFERENCES

  1. O’Neill JD, Guenthart BA, Kim J, Chicotka S, Queen D, Fung K, et al. Cross-circulation for extracorporeal support and recovery of the lung. Nat Biomed Eng. 2017; 1: 1-15.
  2. Guenthart BA, O’Neill JD, Kim J, Queen D, Chicotka S, Fung K, et al. Regeneration of severely damaged lungs using an interventional cross-circulation platform. Nat Commun. 2019;10: 1-16.
  3. Hozain AE, Tipograf Y, Pinezich MR, Cunningham KM, Donocoff R, Queen D, et al. Multi-day maintenance of extracorporeal lungs using cross-circulation with conscious swine. J Thorac Cardiovasc Surg. 2019; 159: 1640-1653.
  4. Hozain AE, O’Neill JD, Pinezich MR, Tipograf Y, Donocoff R, Cunningham KM, et al. Xenogeneic cross-circulation for extracorporeal recovery of injured human lungs. Nat Med. 2020; 26:
    1102-1113.
  5. O’Neill JD, Guenthart BA, Hozain AE, Bacchetta M. Xenogeneic support for the recovery of human donor organs. J Thorac Cardiovasc Surg. 2022; 163: 1563-1570.
  6. Guenthart BA, O’Neill JD, Bacchetta M. Cannulation strategies in ex vivo lung perfusion. ASAIO Journal. 2022; 68(11): 222.
  7. Wu WK, Guenthart BA, O’Neill JD, Hozain AE, Tipograf Y, Ukita R, et al. Technique for xenogeneic cross-circulation to support human donor lungs ex vivo. J Heart Lung Transplant. 2023; 42(3):
    335-344.
  8. Wu WK, Stier MT, Stokes JW, Ukita R, Patel YJ, Cortelli M, et al. Immune characterization of a xenogeneic human lung cross-circulation support system. Sci Adv. 2023; 9(13): 1-13.
  9. Tracy KM, Harris TR, Petrovic M, Cortelli M, Tucker W, François S, et al. Lung rehabilitation using xenogeneic cross-circulation does not lead to hyperacute rejection in a human lung transplantation model. J Heart Lung Transplant. 2025; 44(7): 1122-1134.
  10. Pinezich MR, O’Neill JD, Guenthart BA, Kim J, Vila OF, Ma SP, et al. Theranostic methodology for ex vivo donor lung rehabilitation. Med. 2025; 6(7): 100644.

Contact us

Get in touch

760 Parkside Avenue
Brooklyn, NY 11226

+1 (212) 689-9005

info@xylyxbio.com

Name